Trial
NCT04251715
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
OHSU Knight Cancer Institute
Collaborators
Oregon Health and Science University
Condition
Liver and Intrahepatic Bile Duct Carcinoma
Intervention
Dexamethasone
Why stopped
change in standard-of-care systemic therapy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-25